Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00678145 · ClinicalTrials.gov registry record · Phase 2

Mechanisms of Hypoglycemia Associated Autonomic Failure

A Phase 2 study, sponsored by Albert Einstein College of Medicine.

Terminated
Registry status
Phase 2
Development phase
39
Enrollment target

NCT00678145 is a Phase 2 study that was terminated before completion, run by Albert Einstein College of Medicine. The registered enrollment target is 39 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00678145, a Phase 2 study, was terminated before completion, sponsored by Albert Einstein College of Medicine.

TERMINATED
Registry status
Phase 2
Development phase
39 participants
Enrollment target

Study Summary

Intensive glucose control in type 1 diabetes mellitus (T1DM) is associated with clear health benefits. However, despite development of insulin analogs, pump/multi-dose treatment and continuous glucose monitoring, maintaining near-normal glycemia remains an elusive goal for most patients, in large part owing to the risk of hypoglycemia. T1DM patients are susceptible to hypoglycemia due to defective counterregulatory responses (CR) characterized by: 1) deficient glucagon release during impending/early hypoglycemia; 2) additional hypoglycemia-associated autonomic failure (HAAF) and exercise-associated autonomic failure (EAAF) that blunt the sympathoadrenal responses to hypoglycemia following repeated episodes of hypoglycemia or exercise as well as degrading other CR; and 3) hypoglycemia unawareness (HU), lowering the threshold for symptoms that trigger behavioral responses (e.g. eating). Thus, the risk of hypoglycemia in T1DM impedes ideal insulin treatment and leads to defaulting to suboptimal glycemic control. There are two approaches that could resolve this important clinical problem: 1) perfection of glucose sensing and insulin and glucagon delivery approaches (bioengineered or cell-based) that mimic normal islet function and precisely regulate glucose continuously, or 2) a drug to enhance or normalize the pattern of CR to hypoglycemia. Despite much research and important advances in the field, neither islet transplantation nor biosensor devices have emerged as viable long-term solutions for the majority of patients. Over the past several years, the Diabetes Research Center laboratory at Albert Einstein College of Medicine has explored the approach of enhancing CR by examining mechanisms responsible for HAAF/EAAF and searching for potential pharmacological methods to modulate the CR to hypoglycemia. The work by the laboratory has led to a paradigm shift in the field of hypoglycemia, exemplified by the novel hypothesis and published experimental data supporting a ro

Interventions

  • DRUG Epinephrine
  • BEHAVIORAL exercise
  • DRUG naloxone
  • DRUG Morphine sulfate
  • DIETARY_SUPPLEMENT fructose

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2008-03
Est. Completion 2018-08
Phase Phase 2

Sponsor

Albert Einstein College of Medicine

175 total trials

What the Registry Record Tells You About NCT00678145

The ClinicalTrials.gov registry entry for NCT00678145 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 5 interventions - of which Epinephrine is the first listed.

NCT00678145 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00678145 about?

NCT00678145 is a clinical study titled "Mechanisms of Hypoglycemia Associated Autonomic Failure". Intensive glucose control in type 1 diabetes mellitus (T1DM) is associated with clear health benefits. However, despite development of insulin analogs, pump/multi-dose treatment and continuous glucose monitoring, maintaining near-normal glycemia remains an elusive goal for most patients, in large pa...

What is the current status of trial NCT00678145?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2008-03. Estimated completion is 2018-08.

What interventions are being tested in trial NCT00678145?

The interventions under investigation include: Epinephrine (DRUG), exercise (BEHAVIORAL), naloxone (DRUG), Morphine sulfate (DRUG), fructose (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT00678145?

This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.